Accelerating precision medicine of cancer with SomaScan® proteomics

Accelerating precision medicine of cancer
with SomaScan proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology — the SomaScan Platform, which measures 7,000 proteins — to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will also be presented.

Learn about:

  • Plasma protein biomarkers for predicting response to immunotherapy in metastatic melanoma
  • Serum protein biomarkers for differential diagnosis of oral squamous cell carcinoma
  • Plasma protein biomarkers for pancreatic cancer
  • Exosome protein biomarkers for pancreatic cancer
  • Urine protein biomarkers for pancreatic cancer and triple negative breast cancer
  • Pre-diagnostic plasma protein biomarkers for early detection of hepatocellular cancer

Towia Libermann, PhD

Towia Libermann, PhD

Towia Libermann, PhD, is Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. He is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center and of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core.

Accelerating precision medicine of cancer with SomaScan proteomics

A presentation by Towia Libermann, PhD

Share with colleagues

More webinars

WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure

Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.

Learn more

WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC

In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.

Learn more

WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups

Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or‍ negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched‍ healthy controls.

Learn more

Explore webinars in our interactive viewer